Skip to content
MARKETS / BALCAO / OTLC
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Oncotelic Therapeutics, Inc. OTLC

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$249.3M
In brief

What this company does

The Company is currently developing OT-101, in addition to five additional compounds, for various cancers and COVID-19 through its joint venture, GMP Biotechnology Limited, with Dragon Overseas Capital, Limited, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The Company also acquired apomorphine for Parkinson's Disease, erectile dysfunction and female sexual dysfunction. In addition, the Company is evaluating the further development of its product candidates OXi4503, as a treatment for acute myeloid leukemia and myelodysplastic syndromes, and CA4P, in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. The Company is also planning to address the animal health industry through Pet2DAO. We are a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. In this connection, in March 2022, the Company entered into a joint venture with Dragon, affiliates of Golden Mountain Partners, LLC, to form GMP Biotechnology, Limited.

Written from the business description in Oncotelic Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.1 · Net income -7.9
0.8M1.6M-4.0M-8.0M200920112013201520172019202120232025
Compound annual growth
−65.7%
−3.0%
+265.7%
+289.3%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2023 · Operating -9497.2% · Net -11723.0%
-5000%-10000%200920112013201520172019202120232025
ROE
FY2025 · ROE 184.0%
-5000%200920112013201520172019202120232025

Each USD of equity produced 184 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2015 · FCF -11.9
-10M-20M200920112013201520172019202120232025

Total assetsUSD 393.1M
EquityUSD 262.8M
Gross debtUSD 3.5M
Current ratio0.07×

Equity funds 67% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B··0.0··0.0······0.00.0···
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B····−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.1··········0.00.0····
Net income $B0.2−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··········−0.0−0.0····−0.0
EPS, diluted $0.59−0.01−0.020.01−0.03−0.11−0.11−0.12−0.52−0.51−0.54−0.75−4.67−5.48−10.37−71.60−13.15
Dividend / sh $·················
Payout %·················
ROE %184.0−44.4−50.137.2−95.2−66.3−68.6−72.0−229.9−72.1−50.2−72.2−156.3−121.1−545.1−8739.0−426.4
Shares out B0.440.410.400.390.380.090.080.010.030.030.030.020.010.000.000.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image